Osteoporosis has afflicted humans for thousands of years, but the disease did not get its name until the 1830s, when French pathologist Jean Lobstein coined the term from the Greek words for “porous bone.” The story of how we went from noticing fragile skeletons in ancient burial sites to understanding the molecular machinery behind bone loss spans roughly two centuries of formal medicine and millennia of unrecognized suffering. Along the way, the disease shifted from an obscure anatomical curiosity to a global public health priority, driven by breakthroughs in hormonal science, imaging technology, and molecular biology.
Porous Bones in the Ancient World
Long before anyone had a name for it, osteoporosis was leaving its mark on human skeletons. Researchers studying Egyptian mummies stored in Italian museums examined 33 bodies dating from the New Kingdom period (roughly 1550–1070 BC) through the Roman period. Using conventional X-rays, they identified osteoporosis in four of those individuals, three women and one man, all estimated to be over 35 years old. Life expectancy in ancient Egypt hovered between 35 and 45 years, with only about one in ten people surviving past 50, so the fact that bone loss showed up at all tells us something about how quickly aging could erode the skeleton even in antiquity.1Journal of the Royal College of Physicians of Edinburgh. The history of osteoporosis: why do Egyptian mummies have porotic bones?
Archaeological digs across many time periods and cultures have turned up further evidence. Vertebral crush fractures are the most commonly found osteoporosis-related fracture in ancient bone collections, though they probably caused less hardship in daily life than hip fractures. Hip fractures, by contrast, rarely appear in archaeological material, yet historical texts make clear that people in past centuries were well aware of them and their devastating consequences.2International Journal of Osteoarchaeology. An investigation of historical and archaeological evidence for age‐related bone loss and osteoporosis The gap between what bones survive in the ground and what people actually experienced is a recurring puzzle in paleopathology. Individuals who broke a hip often died soon afterward, meaning their remains may have been buried or treated differently, or the fractures may simply be underrepresented in surviving collections.
Naming the Disease in the Nineteenth Century
The word “osteoporosis” entered medical language around 1830, coined by Jean Lobstein, a French-German pathologist working in Strasbourg. Lobstein noticed that certain bones he examined during autopsies were riddled with abnormally large pores. He used the term to distinguish this kind of generalized bone fragility from localized softening or tumors. At the time, the observation was purely descriptive. Nobody understood why some people’s bones became porous with age while others’ did not, and the condition was not considered a disease in its own right. It was more of an anatomical footnote, something pathologists noticed when cutting into cadavers.
For most of the nineteenth century, osteoporosis sat in the background of medical science. Physicians recognized that elderly patients, especially women, were prone to fractures, but there was no framework connecting those fractures to a single underlying cause. Bone loss was seen as a normal, unremarkable part of aging rather than a treatable condition. That perception began to shift only in the early twentieth century, as endocrinology started to take shape as a field and researchers began connecting hormones to bone metabolism.
Fuller Albright and the Hormonal Link
The single most important figure in turning osteoporosis from an anatomical curiosity into a recognized clinical disease was Fuller Albright, an American endocrinologist at Massachusetts General Hospital. In 1941, Albright published a landmark paper describing what he called “postmenopausal osteoporosis,” arguing that the dramatic bone loss many women experienced after menopause was driven by the drop in estrogen.3JAMA. Postmenopausal Osteoporosis: Its Clinical Features This was a radical reframing. Instead of “old bones break,” Albright proposed a specific hormonal mechanism and, by extension, raised the possibility that the process could be slowed or reversed.
Albright’s work drew attention to the fact that osteoporosis was not simply the price of getting older. It was tied to measurable changes in the body’s chemistry. His observations laid the groundwork for decades of research into estrogen replacement therapy as a way to preserve bone mass. But the field still lacked a reliable way to measure how much bone a living person had lost, which meant diagnosis remained largely guesswork until imaging technology caught up.
The Diagnostic Revolution
For much of the twentieth century, osteoporosis was essentially invisible until it announced itself with a fracture. Standard X-rays could show broken vertebrae or a crumbling hip, but they were poor at detecting the gradual thinning of bone that precedes a fracture. A patient had to lose a substantial portion of bone mass before it showed up on a plain film. Doctors relied on clinical suspicion, patient history, and sometimes crude measurements of height loss to identify who might be at risk.
That changed with the development of dual-energy X-ray absorptiometry, commonly known as DXA. DXA scans measure bone mineral density at the spine and hip with far greater precision than ordinary X-rays, and they do so with very low radiation exposure. The technology gave clinicians, for the first time, a practical tool to identify bone loss before a fracture happened.4PubMed Central. The role of DXA bone density scans in the diagnosis and treatment of osteoporosis
DXA became clinically meaningful in 1994, when the World Health Organization established a standardized definition of osteoporosis based on DXA results. A T-score of −2.5 or lower at the hip or spine was designated as the diagnostic threshold. That cutoff was chosen because it produced a prevalence that matched the observed lifetime risk of fragility fractures in Caucasian women aged 50 and older.5PubMed. Revision of the 1994 World Health Organization T-score definition of osteoporosis for use in older East Asian women and men to reconcile it with their lifetime risk of fragility fracture The WHO definition transformed osteoporosis from a vague clinical impression into a condition with a hard diagnostic number, which in turn drove screening programs, treatment guidelines, and insurance coverage.
The T-score threshold has its critics. It was calibrated primarily for white postmenopausal women, and researchers have since questioned whether the same cutoff applies well to men, to younger patients, and to people of different ethnic backgrounds. Efforts to revise or supplement the criteria for broader populations continue, but the 1994 definition remains the bedrock of clinical practice worldwide.
Molecular Discoveries That Reshaped Understanding
Bone might look static, but it is constantly being torn down and rebuilt by competing teams of cells. Osteoclasts break down old bone; osteoblasts build new bone in its place. In healthy adults these two processes stay roughly in balance. In osteoporosis, resorption outpaces formation, and the skeleton gradually hollows out. The broad outlines of this process were understood by the mid-twentieth century, but the molecular signals controlling it remained a mystery until a burst of discoveries in the 1990s and early 2000s.
The first major breakthrough was the identification, in the mid-1990s, of a signaling system called RANKL/RANK/OPG. RANKL is a protein that triggers the formation, activation, and survival of osteoclasts. When it binds to its receptor RANK on the surface of osteoclast precursors, bone breakdown accelerates. A natural counterweight called OPG acts as a decoy, intercepting RANKL before it can reach RANK and thereby protecting bone from excessive resorption.6PubMed Central. Functions of RANKL/RANK/OPG in bone modeling and remodeling Understanding this system was transformative because it pointed directly toward a drug target: if you could block RANKL pharmacologically, you could slow bone loss. That insight eventually led to the development of denosumab, a monoclonal antibody that mimics OPG’s protective role.
On the bone-building side, researchers made an equally striking discovery by studying rare genetic conditions. People with sclerosteosis and Van Buchem disease have unusually dense, thick bones. Genetic analysis revealed that both conditions involve the SOST gene, which codes for a protein called sclerostin. Sclerostin is produced almost exclusively by osteocytes, the cells embedded within bone, and it acts as a brake on new bone formation.7PubMed. The sclerostin story: from human genetics to the development of novel anabolic treatment for osteoporosis In people missing functional sclerostin, the brake is released and bone builds up far beyond normal levels.8PubMed Central. Role and mechanism of action of sclerostin in bone The logic for drug development was straightforward: if blocking sclerostin causes bones to grow thicker, then an antibody against sclerostin might help people with osteoporosis rebuild lost bone. That reasoning produced romosozumab, which reached the clinic in 2019.
The Long Road From Estrogen to Modern Drugs
In 1970, there were no drugs under formal study for osteoporosis. Estrogen was in use, but the correct dose for preventing bone loss was poorly understood.9Menopause. Advances in osteoporosis from 1970 to 2018 Throughout the 1970s and 1980s, treatment options remained limited and somewhat haphazard. By the mid-1990s, clinical trials had demonstrated fracture-reduction benefits for a handful of agents, including etidronate, estrogen patches, calcitonin, and active vitamin D, though results with fluoride were mixed.10PubMed. Present and future of osteoporosis therapy
The real sea change came with bisphosphonates. These drugs are chemical cousins of pyrophosphate, a natural molecule the body uses to regulate mineralization. Researchers originally studied them as potential inhibitors of unwanted calcification, but they turned out to be remarkably effective at slowing bone breakdown as well.11PubMed. Bisphosphonates: the first 40 years Alendronate, the bisphosphonate that would become the most widely prescribed osteoporosis drug in the world, was synthesized in the 1970s, patented for bone-disease use in the 1980s, licensed by Merck in 1988, and eventually proven in clinical trials to reduce bone turnover, increase bone density, and lower the risk of vertebral fractures in postmenopausal women.12PubMed. History of alendronate When it reached pharmacies in the mid-1990s under the brand name Fosamax, it gave millions of patients their first effective, widely accessible treatment.
Bisphosphonates remain a mainstay, but the treatment landscape has expanded considerably since then. The field now distinguishes between two broad classes of osteoporosis drugs: antiresorptive agents, which slow bone breakdown, and anabolic agents, which stimulate new bone formation. The first anabolic drug, teriparatide (a fragment of parathyroid hormone), was approved in 2002. A second parathyroid hormone receptor agonist, abaloparatide, followed. Romosozumab, the sclerostin antibody described earlier, represents a newer category with a dual effect: it boosts bone formation while simultaneously reducing resorption.13PubMed Central. Anabolic therapy for osteoporosis: update on efficacy and safety The progression from “nothing under study” in 1970 to a multi-class pharmaceutical toolkit within about four decades is one of the more rapid treatment revolutions in chronic disease.
The Slow Recognition of Male Osteoporosis
For most of its modern medical history, osteoporosis was framed almost exclusively as a disease of postmenopausal women. Albright’s foundational work centered on estrogen loss, DXA screening programs targeted women, and clinical trials enrolled predominantly female participants. Men were largely left out of the conversation, and many still are.
This gap is not trivial. Men account for a significant share of osteoporotic fractures, and hip fractures in older men carry a higher mortality rate than in women. Yet much of what we know about bone biology comes from studies of female patients, and the well-established link between menopause and osteoporosis can lead to an underestimation of the condition in men.14PubMed Central. The osteoporotic male: overlooked and undermanaged? The gradual, age-related decline in testosterone that men experience does contribute to bone loss, but the relationship is less dramatic and less well studied than estrogen’s role in women.15PubMed Central. Male Hypogonadism and Osteoporosis: The Effects, Clinical Consequences, and Treatment of Testosterone Deficiency in Bone Health As life expectancy rises and more men survive into their seventies and eighties, the burden of male osteoporosis is becoming harder to ignore. Guidelines have gradually expanded to include men in screening recommendations, but awareness still lags.
Secondary Causes and the Expanding Definition
Albright’s original framing of osteoporosis as a postmenopausal phenomenon was a crucial first step, but it told only part of the story. Throughout the twentieth century, clinicians recognized a growing list of conditions and medications that could erode bone independently of menopause or aging. Glucocorticoid-induced osteoporosis, caused by long-term use of drugs like prednisone, emerged as the most common form of secondary bone loss.16PubMed Central. Glucocorticoid-induced osteoporosis: lessons from Cushing’s syndrome Thyroid disorders, celiac disease, chronic kidney disease, certain cancers, and a range of medications from anticonvulsants to aromatase inhibitors all found their way onto the list of secondary causes.
The recognition of secondary osteoporosis matters historically because it forced a conceptual shift. The disease was no longer a single entity with a single hormonal explanation. It became an umbrella term for any significant loss of bone density and structural integrity, regardless of cause. That broader definition changed clinical practice: today, when a patient presents with unexpectedly low bone density or a fragility fracture, the workup includes screening for secondary causes rather than simply attributing the problem to age or menopause.
An Evolutionary Angle on Fragile Bones
One of the more thought-provoking chapters in the osteoporosis story comes from evolutionary biology. Comparisons of bone density across species and across human history suggest that our skeletons have become lighter and more fragile over the past several thousand years, and not just because we live longer. Research examining trabecular bone density in lower-limb joints found a clear and uniform decline among all recent humans in the Holocene, the geological epoch covering roughly the last 12,000 years. Fossil hominins and living non-human primates show higher trabecular density values that are broadly similar to each other, suggesting the decline is specific to modern humans rather than a general primate trend.17The FASEB Journal. Revisiting the Evolution of Low Trabecular Bone Density in Modern Humans
The leading explanation is sedentism. As humans transitioned from nomadic hunter-gatherer lifestyles to settled agriculture and eventually to modern desk-bound existence, the mechanical loading on their skeletons dropped. Bone adapts to the forces placed on it, a principle formalized by the nineteenth-century anatomist Julius Wolff. Remove those forces and the skeleton responds by building less. In this reading, osteoporosis is not purely a disease of old age. It is, at least in part, a mismatch between the skeleton we evolved and the lives we now lead.
Bone Loss in Space
That mismatch becomes extreme in microgravity. Astronauts aboard the International Space Station lose roughly one to two percent of their bone mass per month in weight-bearing regions like the hip and spine, a rate that dwarfs anything seen in earthbound osteoporosis.18npj Microgravity. The effects of microgravity on bone structure and function Without gravity pulling on the skeleton, the signals that normally stimulate bone formation weaken, and resorption dominates. The result is a form of accelerated, mechanically driven osteoporosis compressed into months rather than decades.
Spaceflight-related bone loss remains one of the major unresolved health risks for long-duration missions. Current countermeasures, including resistance exercise regimens and pharmacological interventions, reduce the problem but do not eliminate it.19PubMed Central. The Effect of Space Travel on Bone Metabolism: Considerations on Today’s Major Challenges and Advances in Pharmacology Whether astronauts fully recover their bone density after returning to Earth, and what happens on missions lasting a year or more, are active research questions with real stakes as agencies plan crewed trips to Mars. In a sense, space medicine has become an unexpected extension of the osteoporosis story, testing the same biological principles Albright first described, just in a setting he never imagined.